The Role of Combination Drugs in the Medicare Drug Price Negotiation Program

This Viewpoint explores the concept of pharmaceutical manufacturers reformulating drugs to avoid selection for price negotiation and the importance of distinguishing between biologically active and inactive combination drugs.

Corresponding Author: Rachel E. Sachs, JD, MPH, School of Law, Washington University in St Louis, 1 Brookings Dr, St Louis, MO 63130 (rsachs@wustl.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.